Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, P.R. China.
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Inflamm Bowel Dis. 2022 Nov 2;28(11):1766-1775. doi: 10.1093/ibd/izac094.
Inflammatory bowel disease (IBD), characterized by chronic inflammation of the gastrointestinal tract, is a global health care problem. Compelling evidence shows sex differences regarding the prevalence, pathophysiology, clinical presentation, and treatment outcome of IBD. Sex hormones, including estrogen, progesterone, and androgen, have been proposed to have a role in the pathogenesis of sexual dimorphism in IBD. Clinical and experimental data support the modulatory effects of sex hormones on various clinical characteristics of the disease, including intestinal barrier dysfunction and mucosal immune activation. Additionally, the potential role of sex hormones in the modulation of gut microbiota is attracting increasing attention. Here, we discuss the sex dimorphic disease profile and address the potential mechanisms involved in the sex-specific pathogenesis of IBD. Improved understanding of these sex differences in the clinic could improve the knowledge of patients with IBD with heterogeneous disease profiles.
炎症性肠病(IBD)以胃肠道的慢性炎症为特征,是一个全球性的医疗保健问题。大量证据表明,IBD 的患病率、病理生理学、临床表现和治疗结果存在性别差异。雌激素、孕激素和雄激素等性激素被认为在 IBD 的性别二态性发病机制中起作用。临床和实验数据支持性激素对疾病的各种临床特征的调节作用,包括肠道屏障功能障碍和黏膜免疫激活。此外,性激素在调节肠道微生物群中的作用也引起了越来越多的关注。在这里,我们讨论了疾病表现的性别二态性,并探讨了 IBD 性别特异性发病机制中涉及的潜在机制。在临床中更好地理解这些性别差异,可以提高对具有不同疾病特征的 IBD 患者的认识。